Sanofi SA ended 2025 with sales of €43.6 billion and net income of €7.8 billion as it continued to reap the benefits of Dupixent, its anti-inflammatory drug developed with Regeneron Pharmaceuticals and first approved in 2017. Dupixent generated sales of €15.7 billion, or 36% of group sales, as it continued to experience strong demand from patients with asthma and other chronic diseases. The annual results were announced on 29 January.
Novartis started construction on 6 February of a new biomedical research centre in San Diego, US, which is one of three global hubs for the company’s drug discovery activities. The other two hubs are in Cambridge, US, and Basel, Switzerland. The move is part of a previously announced $23 billion investment in the US that will also include a new manufacturing site in North Carolina and a site in California to produce radioligand therapies.
The Roche Group delivered revenue of CHF 61.5 billion ($79.2 billion) in 2025 – an increase of 2% in Swiss francs and 7% at constant exchange rates and driven by five products covering a diverse group of diseases. The revenue was sufficiently large to offset the company’s loss of income in the US from six legacy products, including Herceptin, the world’s first targeted therapy for cancer.
Oncology Review
Oncology drug approvals rise, led by China
Public Policy
A plan to empower the EU single market
Advanced Therapies
A business model for cell and gene therapies
Regulation and Policy
Contours of the new EU pharma
legislation are visible
Stock Market Performance
The focus is now on politics
Commentary
Reflections on JP Morgan meeting
A business model for cell and gene therapies
(119.24 KB)
